nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—OPRM1—telencephalic ventricle—malignant glioma	0.199	0.335	CbGeAlD
Methylnaltrexone—Buprenorphine—CYP2C18—malignant glioma	0.0913	0.675	CrCbGaD
Methylnaltrexone—OPRM1—brainstem—malignant glioma	0.0538	0.0907	CbGeAlD
Methylnaltrexone—OPRM1—telencephalon—malignant glioma	0.0477	0.0805	CbGeAlD
Methylnaltrexone—Hydromorphone—PTGS1—malignant glioma	0.0439	0.325	CrCbGaD
Methylnaltrexone—OPRK1—central nervous system—malignant glioma	0.0381	0.0643	CbGeAlD
Methylnaltrexone—OPRK1—cerebellum—malignant glioma	0.0373	0.0628	CbGeAlD
Methylnaltrexone—OPRM1—midbrain—malignant glioma	0.0343	0.0578	CbGeAlD
Methylnaltrexone—OPRM1—spinal cord—malignant glioma	0.0334	0.0564	CbGeAlD
Methylnaltrexone—OPRK1—brain—malignant glioma	0.0303	0.051	CbGeAlD
Methylnaltrexone—OPRM1—central nervous system—malignant glioma	0.0271	0.0457	CbGeAlD
Methylnaltrexone—CYP2D6—brainstem—malignant glioma	0.0216	0.0363	CbGeAlD
Methylnaltrexone—OPRM1—brain—malignant glioma	0.0215	0.0363	CbGeAlD
Methylnaltrexone—CYP2D6—telencephalon—malignant glioma	0.0191	0.0323	CbGeAlD
Methylnaltrexone—CYP2D6—central nervous system—malignant glioma	0.0109	0.0183	CbGeAlD
Methylnaltrexone—CYP2D6—cerebellum—malignant glioma	0.0106	0.0179	CbGeAlD
Methylnaltrexone—CYP2D6—brain—malignant glioma	0.00863	0.0146	CbGeAlD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.00115	0.00422	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCR3—malignant glioma	0.00113	0.00415	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—PIK3CA—malignant glioma	0.0011	0.00405	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LATS2—malignant glioma	0.0011	0.00403	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.00104	0.00384	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—BDKRB2—malignant glioma	0.00103	0.0038	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—F2—malignant glioma	0.001	0.0037	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LATS1—malignant glioma	0.000984	0.00362	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTT1—malignant glioma	0.000973	0.00358	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCR3—malignant glioma	0.000954	0.00351	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—KNG1—malignant glioma	0.000939	0.00346	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—PTGS1—malignant glioma	0.000912	0.00335	CbGpPWpGaD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—AKT1—malignant glioma	0.000899	0.00331	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—BDKRB2—malignant glioma	0.000873	0.00321	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR4—malignant glioma	0.000859	0.00316	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—malignant glioma	0.000838	0.00308	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LATS1—malignant glioma	0.000831	0.00306	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.000797	0.00293	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—KNG1—malignant glioma	0.000794	0.00292	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR4—malignant glioma	0.00078	0.00287	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR4—malignant glioma	0.000726	0.00267	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—malignant glioma	0.000708	0.0026	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL8—malignant glioma	0.000707	0.0026	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—RTEL1—malignant glioma	0.000682	0.00251	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—GSTP1—malignant glioma	0.000675	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.000674	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—AKT1—malignant glioma	0.000667	0.00245	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—GSTP1—malignant glioma	0.000665	0.00245	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDK—malignant glioma	0.000664	0.00244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR4—malignant glioma	0.000659	0.00242	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCR3—malignant glioma	0.000638	0.00235	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DTX1—malignant glioma	0.000634	0.00233	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—F2—malignant glioma	0.000607	0.00223	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL8—malignant glioma	0.000597	0.0022	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—BDKRB2—malignant glioma	0.000584	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCR3—malignant glioma	0.000579	0.00213	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000562	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDK—malignant glioma	0.000562	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCR3—malignant glioma	0.000539	0.00198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DTX1—malignant glioma	0.000536	0.00197	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—KNG1—malignant glioma	0.000531	0.00195	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—BDKRB2—malignant glioma	0.00053	0.00195	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—F2—malignant glioma	0.000513	0.00189	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SUFU—malignant glioma	0.000504	0.00185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HEY2—malignant glioma	0.000497	0.00183	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—BDKRB2—malignant glioma	0.000493	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCR3—malignant glioma	0.00049	0.0018	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GFAP—malignant glioma	0.000486	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KNG1—malignant glioma	0.000482	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000475	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPHK1—malignant glioma	0.00047	0.00173	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HEY1—malignant glioma	0.000461	0.00169	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR4—malignant glioma	0.000461	0.00169	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—KNG1—malignant glioma	0.000449	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—BDKRB2—malignant glioma	0.000448	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIST1H3B—malignant glioma	0.000447	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—malignant glioma	0.000428	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MMP3—malignant glioma	0.000427	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SUFU—malignant glioma	0.000426	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HEY2—malignant glioma	0.00042	0.00155	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GFAP—malignant glioma	0.000411	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAG2—malignant glioma	0.000408	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KNG1—malignant glioma	0.000407	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPHK1—malignant glioma	0.000397	0.00146	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COX8A—malignant glioma	0.000392	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR4—malignant glioma	0.000389	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HEY1—malignant glioma	0.000389	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIST1H3B—malignant glioma	0.000378	0.00139	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—malignant glioma	0.000362	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MMP3—malignant glioma	0.000361	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—H3F3A—malignant glioma	0.000346	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAG2—malignant glioma	0.000345	0.00127	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—F2—malignant glioma	0.000343	0.00126	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR3—malignant glioma	0.000342	0.00126	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ASMT—malignant glioma	0.000333	0.00123	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NTRK2—malignant glioma	0.000333	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—YWHAE—malignant glioma	0.000333	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FLT1—malignant glioma	0.000332	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DUSP6—malignant glioma	0.00033	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CG—malignant glioma	0.000328	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAG1—malignant glioma	0.000326	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH3—malignant glioma	0.000324	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FBXW7—malignant glioma	0.000319	0.00117	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCAN—malignant glioma	0.000313	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BDKRB2—malignant glioma	0.000313	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—F2—malignant glioma	0.000312	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT2—malignant glioma	0.0003	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—malignant glioma	0.000298	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTPN11—malignant glioma	0.000293	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—H3F3A—malignant glioma	0.000292	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH2—malignant glioma	0.000291	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—F2—malignant glioma	0.00029	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR3—malignant glioma	0.000289	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—malignant glioma	0.000289	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KNG1—malignant glioma	0.000285	0.00105	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—YWHAE—malignant glioma	0.000281	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NTRK2—malignant glioma	0.000281	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FLT1—malignant glioma	0.00028	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DUSP6—malignant glioma	0.000279	0.00103	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—malignant glioma	0.000278	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAG1—malignant glioma	0.000275	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH3—malignant glioma	0.000274	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT2—malignant glioma	0.000273	0.001	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NTRK1—malignant glioma	0.000271	0.000998	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FBXW7—malignant glioma	0.00027	0.000992	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BDKRB2—malignant glioma	0.000265	0.000973	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—F2—malignant glioma	0.000263	0.000969	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—malignant glioma	0.000262	0.000964	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT2—malignant glioma	0.000254	0.000934	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—IDH2—malignant glioma	0.000252	0.000929	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP3—malignant glioma	0.000252	0.000928	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—malignant glioma	0.000252	0.000927	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000252	0.000926	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN2B—malignant glioma	0.00025	0.00092	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTPN11—malignant glioma	0.000248	0.000911	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH2—malignant glioma	0.000246	0.000905	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—malignant glioma	0.000244	0.000897	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTK2—malignant glioma	0.000243	0.000893	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—malignant glioma	0.000242	0.000889	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KNG1—malignant glioma	0.000241	0.000885	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—malignant glioma	0.000239	0.000878	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2B6—malignant glioma	0.000237	0.000873	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NCOR1—malignant glioma	0.000237	0.000873	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RAF1—malignant glioma	0.000234	0.000861	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—malignant glioma	0.000231	0.00085	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT2—malignant glioma	0.000231	0.000848	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NTRK1—malignant glioma	0.000229	0.000844	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—malignant glioma	0.000229	0.000841	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFRA—malignant glioma	0.000227	0.000836	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—malignant glioma	0.000222	0.000815	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPP1—malignant glioma	0.000221	0.000811	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—malignant glioma	0.00022	0.000808	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—IDH1—malignant glioma	0.000217	0.000798	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP3—malignant glioma	0.000213	0.000784	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000213	0.000782	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN2B—malignant glioma	0.000211	0.000778	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SPHK1—malignant glioma	0.00021	0.000773	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—malignant glioma	0.00021	0.000772	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—malignant glioma	0.000209	0.000769	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2C18—malignant glioma	0.000206	0.000757	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTK2—malignant glioma	0.000205	0.000755	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—malignant glioma	0.000204	0.000752	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFB—malignant glioma	0.000204	0.000751	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR1—malignant glioma	0.000203	0.000747	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—malignant glioma	0.000202	0.000742	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NCOR1—malignant glioma	0.000201	0.000738	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—malignant glioma	0.0002	0.000736	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RAF1—malignant glioma	0.000198	0.000728	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—malignant glioma	0.000195	0.000718	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CAV1—malignant glioma	0.000193	0.000711	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—malignant glioma	0.000193	0.00071	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFRA—malignant glioma	0.000192	0.000706	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—malignant glioma	0.000191	0.000703	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPP1—malignant glioma	0.000186	0.000686	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—malignant glioma	0.000186	0.000683	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FN1—malignant glioma	0.000184	0.000677	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—F2—malignant glioma	0.000184	0.000677	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BAD—malignant glioma	0.000182	0.000669	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—malignant glioma	0.00018	0.000663	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—malignant glioma	0.000177	0.000652	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—malignant glioma	0.000177	0.00065	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD80—malignant glioma	0.000176	0.000649	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APC—malignant glioma	0.000176	0.000648	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—malignant glioma	0.000176	0.000648	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—malignant glioma	0.000174	0.000641	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTPN11—malignant glioma	0.000173	0.000637	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFB—malignant glioma	0.000172	0.000634	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR1—malignant glioma	0.000172	0.000631	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—malignant glioma	0.000169	0.000622	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—malignant glioma	0.000166	0.000612	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BRAF—malignant glioma	0.000166	0.000609	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CAV1—malignant glioma	0.000163	0.000601	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—malignant glioma	0.000162	0.000595	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT2—malignant glioma	0.000161	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—malignant glioma	0.000161	0.00059	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS1—malignant glioma	0.000156	0.000574	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2—malignant glioma	0.000156	0.000572	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FN1—malignant glioma	0.000156	0.000572	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—malignant glioma	0.000155	0.00057	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BAD—malignant glioma	0.000154	0.000565	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—malignant glioma	0.000153	0.000564	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—malignant glioma	0.000152	0.00056	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—malignant glioma	0.000152	0.000558	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD80—malignant glioma	0.000149	0.000549	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—malignant glioma	0.000149	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APC—malignant glioma	0.000149	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—malignant glioma	0.000148	0.000545	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—malignant glioma	0.000147	0.000541	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTPN11—malignant glioma	0.000146	0.000538	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCHE—malignant glioma	0.000145	0.000533	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A5—malignant glioma	0.000143	0.000527	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BRAF—malignant glioma	0.00014	0.000515	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—malignant glioma	0.000139	0.000512	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—malignant glioma	0.000139	0.00051	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAF1—malignant glioma	0.000138	0.000509	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—malignant glioma	0.000137	0.000503	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT2—malignant glioma	0.000136	0.000501	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—malignant glioma	0.000136	0.000499	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—malignant glioma	0.000135	0.000497	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—malignant glioma	0.000131	0.000481	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—malignant glioma	0.00013	0.000477	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—malignant glioma	0.00013	0.000477	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—malignant glioma	0.000128	0.000471	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—malignant glioma	0.000125	0.000461	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—malignant glioma	0.000125	0.000461	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—malignant glioma	0.000124	0.000457	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—malignant glioma	0.000124	0.000456	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—malignant glioma	0.000118	0.000433	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—malignant glioma	0.000117	0.000432	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—malignant glioma	0.000117	0.000431	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAF1—malignant glioma	0.000117	0.00043	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—malignant glioma	0.000117	0.000429	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—malignant glioma	0.000116	0.000425	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—malignant glioma	0.000115	0.000424	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—malignant glioma	0.000114	0.00042	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—malignant glioma	0.000114	0.000419	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAT—malignant glioma	0.000112	0.000413	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—malignant glioma	0.00011	0.000403	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOR1—malignant glioma	0.000106	0.00039	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—malignant glioma	0.000106	0.00039	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—malignant glioma	0.000105	0.000388	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—malignant glioma	0.000105	0.000386	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—malignant glioma	0.000105	0.000385	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—malignant glioma	0.000104	0.000384	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—malignant glioma	9.92e-05	0.000365	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—malignant glioma	9.86e-05	0.000363	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—malignant glioma	9.69e-05	0.000357	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—malignant glioma	9.62e-05	0.000354	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—malignant glioma	9.48e-05	0.000349	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—malignant glioma	8.96e-05	0.000329	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—malignant glioma	8.9e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—malignant glioma	8.82e-05	0.000324	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAV1—malignant glioma	8.64e-05	0.000318	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—malignant glioma	8.23e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—malignant glioma	8.19e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—malignant glioma	8.01e-05	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—malignant glioma	7.96e-05	0.000293	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—malignant glioma	7.87e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—malignant glioma	7.6e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—malignant glioma	7.57e-05	0.000278	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—malignant glioma	6.95e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—malignant glioma	6.92e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—malignant glioma	6.73e-05	0.000247	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—malignant glioma	6.72e-05	0.000247	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—malignant glioma	6.03e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—malignant glioma	5.98e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—malignant glioma	5.68e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—malignant glioma	5.21e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—malignant glioma	3.68e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—malignant glioma	3e-05	0.00011	CbGpPWpGaD
